A double-blind, placebo-controlled crossover study of ganglioside GM1 treatment for Alzheimer's disease.
In a double-blind trial, 12 patients with probable Alzheimer's disease were treated for 6 weeks with placebo and 6 weeks with monosialoganglioside (GM1) (100 mg/day i.m.), which potentiates the actions of nerve growth factor. GM1 failed to produce significant improvement in patients' cognitive test performance, suggesting that this is not a viable approach to the treatment of cognitive deterioration in Alzheimer's disease.
Flicker
C
C
Department of Psychiatry, New York University Medical Center, NY 10016.
Ferris
S H
SH
Kalkstein
D
D
Serby
M
M
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D001794:Blood Pressure / Q000187:drug effects; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D005732:Gangliosides / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009414:Nerve Growth Factors / Q000502:physiology; D009483:Neuropsychological Tests; D010919:Placebos; D013268:Stimulation, Chemical; D016896:Treatment Outcome
D005732:Gangliosides; D009414:Nerve Growth Factors; D010919:Placebos; C025447:sialogangliosides